NCT06285071Enrolling by invitation
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 23 (estimated)
- First submitted
- 13 Feb 2024
- Start date
- 8 Aug 2024
- Primary completion date
- 30 Apr 2030
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Haemophilia
- NCT number
- NCT06285071
What you commit to
- Study type: Observational
- Planned participants: 23
- From 8 Aug 2024 to the primary completion date, 30 Apr 2030
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Previous participation in this study. Participation is defined as having given informed consent in this study
Who the study is looking for
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
- The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study
- Male or female patients, regardless of age
- Diagnosis with HAwI/HBwI
Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mutsu general hospital_Pediatrics Coordinator of this site? Confirm its status | Aomori | Japan | Unknown status |
| Kyushu university hospital_Pediatrics Coordinator of this site? Confirm its status | Fukuoka | Japan | Unknown status |
| Sapporo Tokushukai Hospital_Pediatrics Coordinator of this site? Confirm its status | Hokkaido | Japan | Unknown status |
| Kagoshima City Hospital_Pediatrics Coordinator of this site? Confirm its status | Kagoshima | Japan | Unknown status |
| St. Marianna University School of Medicine Hospital_Pediatrics Coordinator of this site? Confirm its status | Kanagawa | Japan | Unknown status |
| Hospital of the University of Occupational And Environmental Health Japan_Pediatrics Coordinator of this site? Confirm its status | Kitakyusyu-shi, Fukuoka | Japan | Unknown status |
| Nanbu Medical Center & Children's Medical Center_Hematology and Oncology Coordinator of this site? Confirm its status | Okinawa | Japan | Unknown status |
| University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology Coordinator of this site? Confirm its status | Okinawa | Japan | Unknown status |
| Tokyo Medical University Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Ogikubo Hospital_Blood Coagulation Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| - Coordinator of this site? Confirm its status | Toshima City | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.